Skip to content

Solar Lighting to Reduce Indoor Air Pollution in Rural Uganda

Solar Lighting Intervention Trial to Reduce Indoor Air Pollution and Improve Adult Respiratory Health in Rural Uganda

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03351504
Enrollment
80
Registered
2017-11-22
Start date
2018-02-07
Completion date
2020-10-31
Last updated
2025-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pollution; Exposure, Pollution Related Respiratory Disorder

Keywords

household air pollution, fine particulate matter, kerosene

Brief summary

This study evaluates the impact of a solar lighting system on kerosene lamp use, levels of indoor air pollution, and health in women living in rural Uganda. Half of the participants will receive the lighting systems immediately, while the other half will receive them after an 18 month delay.

Detailed description

One fifth of the global population relies on kerosene lamps for lighting, yet few studies have focused on kerosene lighting as a source of indoor air pollution. In our preliminary studies performed in Uganda, we show that homes using solar lighting have much lower levels of indoor air pollution compared to homes using kerosene lighting. The primary goal of this study is to determine the extent to which solar lighting will reduce kerosene use and indoor air pollution in rural Uganda, whether this intervention improves lung health, and to identify the role bacteria in our gut have on determining whether or not people will get sick from indoor air pollution.

Interventions

OTHERSolar lighting system

consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.

Sponsors

Mbarara University of Science and Technology
CollaboratorOTHER
Harvard School of Public Health (HSPH)
CollaboratorOTHER
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Randomization will be performed using dummy codes to represent intervention and control groups by an independent statistician; blinding of the intervention to the participants and field team is not possible, but data analysis will take place prior to unblinding.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Women living in Nyakabare Parish, Uganda with no prior history of chronic lung disease

Exclusion criteria

* Current active tuberculosis in any family member

Design outcomes

Primary

MeasureTime frameDescription
Fine particulate matter (PM2.5) and Black Carbon48 hourSampling for PM2.5 and Black Carbon over 48 hours will be collected

Secondary

MeasureTime frameDescription
Blood pressurebaseline, 3 months, 6 months, 12 months after the interventionResting blood pressure
Forced Expiratory Volume in one Second (FEV1)baseline, 3 months, 6 months, 12 months after the interventionPre- and Post- bronchodilator spirometry
Heart rate variabilitybaseline, 3 months, 6 months, 12 months after the interventionResting 10 minute heart rate variability
Daily use of solar lighting system (hours per day)baseline, 3 months, 6 months, 12 months after the interventionA current monitory is installed as part of the solar lighting system that measures the hours per day each light switch is turned on
Qualitative interviewsPost-intervention1:1 qualitative interviews will be performed with participants
Respiratory symptomsbaseline, 3 months, 6 months, 12 months after interventionPresence/absence of respiratory symptoms based on the American Thoracic Society Respiratory Disease questionnaire
Stool microbiomebaseline, 3 months, 6 months, 12 months after the interventionMicrobial sequencing of the stool will be performed

Countries

Uganda, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026